Pulmonx Q3 revenue $13.3M (+25% YoY); net loss $10.2M; maintains FY guidance $49-51M

Pulmonx Corp

2021-Q3 EPS reported -$0.99 revenue$34,708,000

Worldwide revenue $13.3M, up 25% YoY ($10.6M Q3 2020); U.S. revenue $6.9M (+28%), international $6.4M (+22%).
Gross margin improved to 73% (70% prior year); net loss $10.2M ($0.28 loss per share) vs $3.9M ($1.37 loss per share).
Added 18 new U.S. Zephyr Valve treating centers (total 198); positive coverage decisions from Anthem, BCBS Michigan, Horizon NJ (~44M covered lives).
Cash, cash equivalents, and marketable securities totaled $202.6M as of September 30, 2021.
Maintains FY 2021 revenue guidance $49-51M; expects near low end due to COVID headwinds; operating expenses guided $83-85M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.